This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D'Incalci, M. Articles by Faircloth, G. T. Search for Related Content PubMed PubMed Citation Articles by D'Incalci, M. Articles by Faircloth, G. T.

Unique Features of the Mode of Action of ET-743

^a Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri," Milan, Italy; ^b Dipartimento di Biologia Animale, Università degli Studi di Modena e Reggio Emilia, Modena, Italy; ^c PharmaMar SA, Research and Development, Madrid, Spain; ^d PharmaMar USA, Inc., Cambridge Massachusetts, USA

Correspondence: Maurizio D'Incalci, M.D., Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62, 20157 Milan, Italy. Telephone: 39-02-3901-4478; Fax: 39-02-354-6277; e-mail: dincalci{at}marionegri.it

This paper describes the current knowledge of the primary mode of action of a natural product, ecteinascidin 743 (ET-743), derived from the marine tunicate Ecteinascidia turbinata. ET-743 was initially selected for preclinical development because of its potent antitumor activity observed against several human solid tumor types. In vitro, the drug is cytotoxic in the nanomolar range, and in the case of some very sensitive cell lines, in the picomolar range. The large potency differences observed among several solid tumor types indicate that this compound possesses some tumor selectivity, but the molecular basis of these differential effects remains to be elucidated. The present studies were undertaken to evaluate the mechanism of action of ET-743 in this context. The available information on ET-743 binding to DNA and its effects on transcriptional regulation point to a unique behavior of this drug, as it independently affects specific gene transcription in a promoter-dependent way. In addition, ET-743 shows a peculiar pattern of selectivity in cells with different defects in their DNA-repair pathways. These results highlight a unique property of ET-743, possibly explaining why it possesses antitumor activity against tumors that are refractory to standard anticancer drugs, all of which certainly act by mechanisms that are different from that of ET-743.

Key Words. ET-743 • Natural product • Marine compound • Anticancer drug

This article has been cited by other articles:

				G. J. Aune, K. Takagi, O. Sordet, J. Guirouilh-Barbat, S. Antony, V. A. Bohr, and Y. Pommier Von Hippel-Lindau-Coupled and Transcription-Coupled Nucleotide Excision Repair-Dependent Degradation of RNA Polymerase II in Response to Trabectedin Clin. Cancer Res., October 15, 2008; 14(20): 6449 - 6455. [Abstract] [Full Text] [PDF]

				J. A. Casado, P. Rio, E. Marco, V. Garcia-Hernandez, A. Domingo, L. Perez, J. C. Tercero, J. J. Vaquero, B. Albella, F. Gago, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin Mol. Cancer Ther., May 1, 2008; 7(5): 1309 - 1318. [Abstract] [Full Text] [PDF]

				A. B. Herrero, C. Martin-Castellanos, E. Marco, F. Gago, and S. Moreno Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin Cancer Res., August 15, 2006; 66(16): 8155 - 8162. [Abstract] [Full Text] [PDF]

				J. Verweij Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas? J. Clin. Oncol., August 20, 2005; 23(24): 5420 - 5423. [Full Text] [PDF]

				H. Morioka, L. Weissbach, T. Vogel, G. P. Nielsen, G. T. Faircloth, L. Shao, and F. J. Hornicek Antiangiogenesis Treatment Combined with Chemotherapy Produces Chondrosarcoma Necrosis Clin. Cancer Res., March 1, 2003; 9(3): 1211 - 1217. [Abstract] [Full Text] [PDF]

				A. Kanzaki, Y. Takebayashi, X.-Q. Ren, H. Miyashita, S. Mori, S.-i. Akiyama, and Y. Pommier Overcoming Multidrug Drug Resistance in P-Glycoprotein/MDR1-overexpressing Cell Lines by Ecteinascidin 743 Mol. Cancer Ther., December 1, 2002; 1(14): 1327 - 1334. [Abstract] [Full Text] [PDF]